English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Heart failure (HF) is considered the new cardiovascular epidemic of the 21st century, in view of its increasing prevalence, high mortality and enormous costs. In Portugal, HF is a major public health problem for which local and national measures are urgently needed in order to change how HF-related healthcare is currently organized. Pharmacological treatment for heart failure with reduced ejection fraction (HFrEF) is based on careful titration of disease-modifying drugs, such as angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), beta-blockers and aldosterone antagonists. Recently, the PARADIGM-HF study showed that the use of sacubitril-valsartan reduced the risk of cardiovascular events by a further 20% compared to ACE inhibitors and that this new strategy of neurohumoral modulation, instead of merely inhibition, increased survival by one to two years in patients with HFrEF. Given the good results of the PARADIGM-HF study, the use of sacubitril-valsartan has been included in the European Society of Cardiology guidelines as a class IB recommendation in patients who remain symptomatic despite optimal treatment. The latest American guidelines for HF treat-

Uso do Sacubitril/Valsartan no «mundo real»: da teoria à prática clínica